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Abstract
The purpose of this research and literature review is to explore the possible role that gut
microbiome alterations have in the treatment of neurobehavioral diseases; specifically, anxiety and
depression. This literature review searched PubMed, CINAHL, and Clinical Key. A variety of key
terms were used during the search. Due to the field of research being relatively new and limited,
studies from the last ten years and animal models were included in the study. Studies were
excluded due to poor design or if the studies did not include anxiety or depression in the research.
The research shows that there are the are multiple pathophysiologic pathways leading to the
development of anxiety and depression. However, that the gut plays a much larger role in brain
health than previously thought. Additionally, this study explores probiotics as a possible treatment
for depression and anxiety. The research also shows a correlation between pathologic bacteria,
inflammatory pathways, and a reduction in neurotransmitters associated with behavioral health.
The limiting factors of this research was sample size, as many of the studies were conducted as
pilot studies, as well as variations in the dosage of probiotics used in the control trials comparing
probiotics to placebos. Overall, the research shows promise, but larger studies would be needed to
establish guidelines recommending microbiome alterations as a treatment of anxiety and
depression.

Keywords: fecal transplant, gut microbiome, depression, anxiety, mood disorders, and probiotics.
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Introduction
In recent years, there has been extensive research in the microbiome of the gut as a
contributing factor to many diseases. Alterations in the natural flora of the gut has been
implicated in multiple illnesses and more recently in patients with mental health disorders. The
purpose of this study is to critically analyze research regarding the effects of alterations within
our natural gut flora and treatment of neurobehavioral disorders through diet and microbiota
transplantation in comparison to other currently recommended treatments. It is anticipated that
this systematic literature review will show beneficial outcomes to patients using microbiota
transplant as treatment of neurobehavioral disorders with an emphasis on depression and anxiety.
Statement of the Problem
Mental illness is among the most prevalent and costly disorders to treat. A recent study
released by the Centers for Disease Control (2018) found that 8.1% of Americans reported
suffering from symptoms of depression. More than 80% of those affected, reported problems in
multiple areas of their lives. Among patients with depression, as many as 85% reported having
significant anxiety. Patients with diagnosed anxiety had a similar occurrence of depression.
While combination treatment of cognitive behavior therapy and pharmacotherapy have proven
beneficial in many patients, there are many individuals that do not respond to treatments, and
compliance to therapy may be an issue. It is also estimated that 40% of patients with depression
do not seek treatment (CDC, 2018). By identifying changes in the microbiome of patients with
anxiety and depression, treatment can be aimed at treating the underlying pathology and not just
masking symptoms while the patient is receiving treatment.
Research Questions
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In patients with depression or anxiety, do gut microbiota transplants improve symptoms
of depression?
In patients with depression or anxiety, is there an alteration in gut microbiota associated
with the development of moods disorders?
Methods
A literature review was performed using the following electronic databases: PubMed,
CINAHL, and Clinical Key. Both MESH and keywords (fecal transplant, gut microbiome,
depression, anxiety, mood disorders, and probiotics) were used to define a selection of literature
discussing gut microbiome alterations and the use of transplants and modulations as possible
treatment of mood disorders with an emphasis on anxiety and depression. Peer-reviewed studies
from the previous ten years were included, in addition to animal studies. Studies were excluded
due to poor design or not including anxiety or depression in the research.
Literature Review
For many years, it has been known that gut microbiota played major roles in intestinal
function. A review of the literature shows that there is emerging evidence gut microbiomes
effect on overall health, immune function, and the nervous system. There is now evidence of a
bidirectional relationship between the gut microbiota and the brain, which is called the
microbiota-gut-brain (MGB) axis. Alterations within the MGB axis have now been established
in patients suffering from many disease states, including, but not limited to, mood disorder,
autism-spectrum disorder, multiple sclerosis, attention-deficit hypersensitivity disorder, and
obesity. The review shows the underlying pathology is related to bacterial imbalances, gut
leakage, and generalized inflammation (Petra et al., 2015).
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Gut microbiome and the link to depression and anxiety
In order to research gut microbiome alterations as a form of therapy, a bidirectional
relationship must first be established.
Berk et al. (2013) evaluated depression and anxiety as an inflammatory disease. As
experts in their field of psychiatry, this article was written to establish connections between the
gut, inflammation, and the brain. By establishing a pathway, research can be conducted
exploring this pathway, which is the goal of Berk. The main question the study attempts to
answer is what factors cause this low-grade inflammation, which is shown as a clear link to
multiple mental illnesses, including depression and anxiety. In addition to stress, trauma,
smoking, obesity, and diet, it identifies a new pathway between the gut and brain; the toll-like
receptor (TLR) IV pathway. In patients with clinical depression, they have been shown to have
increased levels of immunoglobulin A (IgA) and immunoglobulin M (IgM) directed at the
lipopolysaccharides (LPS) of multiple gram-negative bacteria that are present naturally within
our gut flora. The LPS, also referred to as endotoxins, are toxic substances and activate
proinflammatory cytokines, including: tumor necrosis factor alpha (TNFα), interleukin-1 (IL-1),
and cycloxegenase-2 (COX-2). This systemic immune response indicates that the normal gut
barrier has been broken and has become more permeable. This review discovered that patients
with clinical depression had significantly higher levels of IgM directed at LPS when compared to
patients without depression.
Mood disorders are believed to have multiple pathologic pathways, however, pathways
between the gut and CNS were not hypothesized until recently. This study helps locate specific
chemicals within the gut, serum, and CNS that can be implicated in causing the inflammatory
changes that are present in mood disorders such as, anxiety and depression. Mood disorders have
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long been treated by replacing neurotransmitters with medications. By identifying inflammatory
markers that cause the reduction in neurotransmitters, treatments can be modulated to treat the
inflammation before it causes the reduction in neurotransmitters.
To further establish a gut-brain pathway as a source of the development of mood
disorders, Inserra, A, Rogers, G, Licinio, J, and Wong, M. (2018) evaluated inflammatory
markers and bacteria overgrowth in patients with major depressive disorder (MDD) and anxiety.
Within the study, they propose a bidirectional relationship between the gut and brain function.
They hypothesize that in patients with increased symptoms of depression, there was increased
NLRP3 inflammasome triggering and subsequently increased activation of IL-1 and TNFmediated pathways. This links exposure to psychological stress, immune system function, gut
microbiome composition, and psychological stress response to increased systemic inflammation
and depressive symptoms. The heightened inflammatory state decreases the bioavailability of
neurotransmitters and their precursors.
The goal of this article was to establish a need for further research by establishing the
relationship between the gut and brain. In order to prove this, Inserra et al. (2018) also reviewed
multiple trials that evaluated the microbiome and bacterial families in patients with depression to
help support their hypothesis. They found an increased growth of proinflammatory bacteria and
undergrowth of multiple species of bacteria with anti-inflammatory properties. Additionally,
they evaluated clinical trials that used psychobiotics to treat symptoms of depression. These
clinical trials that were reviewed were minimal in time and had limited participants but showed
promising results. This study shows promise for understanding pathophysiology and etiology of
mood disorders, but the limitation to this study is that further investigation would be required for
definitive treatment recommendations.
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Patients with Major Depressive Disorder (MDD) demonstrate metabolic disorders within
their gut. A study by Xueyan, J., Cui, W., Changxin, W., and Xuemei, Q., (2019) further
investigated the molecular changes and timing of these changes that occur in patients with MDD.
In order to accomplish this, they created an animal model using rats and inducing depression-like
symptoms through chronic unpredictable mild stress (CUMS). In this randomized control trial,
twelve rats were randomly assigned to CUMS or to the control groups- and housed in identical
environments. Within these environments, the rats had access to plain water or sucrose. The rats
were then stressed for four weeks, in random order, every day. Fecal samples, blood samples,
and body weights were collected at identical intervals. The metabalomes in the fecal and blood
samples were evaluated using temporal dynamic gas chromatography-mass spectrometry (GCMS) to establish the exact timing of gut microbiome changes and the development of MDD
symptoms. Additionally, twelve neurotransmitters within the hippocampus were evaluated and
quantified to correlate with fecal and blood samples. The rats were then tested on sugar
preference, grooming time, time spent immobile, rearing counts, and body weight.
The results of this study revealed that after 4 weeks there was statistical significance in
rats that were exposed to the CUMS protocol versus the control rats. CUMS rats had a
significant increase in body weight (P <0.05), time spent immobile (P<0.01), and rearing counts
(P<0.001). There was no statistical significance in sucrose preference or grooming time.
Analysis of the blood and fecal metabolome in the rats exposed to CUMS protocol also showed a
significant remodeling in the rats with depressive-like behaviors (P < 0.05). The quantification of
all twelve neurotransmitters were all significantly lower in the CUMS rats (P < 0.05). These
results indicated that chronic stress can not only change our behavior, but changes the physical
composition of our gut. This link helps to establish the relationship that our gut and brain have in
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regards to neurological health. By measuring the changes in gut microbiome and quantitative
changes in neurotransmitters that directly affect neurological function, a bidirectional link is
clearly established. The strengths of this study are the identical environments and the fact that the
trial was randomized. The weakness of the study is the number of participants. While this study
lays a good foundation, further larger studies involving humans would need to be performed.
In order to establish a causative relationship between gut pathologic bacteria and mental
health, Kelly et al. (2016) transferred gut microbiome from patients with depressive and anxiety
disorders into rats with a depleted gut microbiome. They theorized that by transferring the
microbiome of patients with clinical depression they could confirm the role that gut-brain neural
pathways contribute to. They accomplished this by using 34 patients with clinical depression and
33 control patients with no disease. They were cross matched for age, gender, and ethnicity.
Fecal samples were extracted from all individuals. Rats were pretreated, once daily, with
ampicillin, metronidazole, vancomycin, ciprofloxacin, and imipenem for 28 days. The rats were
then matched for body weight and sex and colonized with the donors’ microbiome 70 hours later.
Booster doses on donor microbiome were given twice weekly to reinforce phenotype and prevent
error.
Statistical analysis used data that was normally distributed according to Shapiro-Wilk test
and using unpaired t tests. Grubb’s test removed outliers. There was found to be no significant
difference in daily diet (t(61) = 2.06, P = 0.05). Assessment of proinflammatory markers showed
significant increase in interleukin 6 (t(62) = 2.69, P=0.009), interleukin 8 (t61) = 2.37, P=0.021),
TNF-α (t(49) = 2.36, P = 0.022), and C-reactive protein (t(45) = 3.6, P = 0.001) when compared
to healthy controls. Gut microbiomes were also found to have statistically altered families of
bacteria in the depression sample (P = 0.03). Rats that received fecal microbiota transplants
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(FMT) from patients with depression demonstrated more behaviors of depression and anxiety.
This was assessed with differences in a reduction of total activity in an open field (P=0.013) and
decreased visit to open arms in the elevated plus maze (P = 0.029). Overall, the study
demonstrated that there is a link between stress, inflammation, gut microbiome, and brain neural
health. The limitation of this study is that it was performed in rats and the correlation to human
microbiota may differ.
Luo et al. (2018) attempted to prove the link between certain bacteria and the
upregulation of inflammatory pathways associated with increased levels of inflammation in
patients with depression and anxiety. They hypothesized that the lack of protective bacteria and
overgrowth of “depressive bacteria” increased basal cortisol levels and inflammation. In order to
prove this theory, they raised germ-free (GF) mice, specific antigen-free mice who were treated
with E. Coli LPS, and mice treated with fecal transplants from patients with clinical depression.
In order to maintain gut microbiomes consistent with their control and test groups, the rats were
kept in identical, sterile environments and fed autoclaved feed.
The results of this study were achieved by comparing the behaviors of GF and
depression-FMT mice. There was a significant difference in which the GF mice showed greater
antianxiety-like behaviors and higher locomotion by performing better in the open-field test
(OFT). They had an increased total distance (p<0.05) and increased center distance (p < 0.001)
when compared to the mice treated with FMT from depressed patients. This portion of the study
is important because it establishes a link between gut microbiome contents and behaviors.
While GF mice showed less behaviors linked to anxiety and depression in initial
evaluation, they were found to have an upregulation in 23 of 84 glucocorticoid receptor
pathways. The altered genes in the GF mice were identified as being highly associated with
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neurological disorders. The upregulation of glucocorticoid pathways causes a heightened stress
reaction to acute stressors by increasing total amount of corticosterone and stress hormones that
are released. This suggests that the lack of pathologic gut microbiome leads to antianxiety and
antidepressant behaviors, but total lack of gut bacteria decreases the host’s ability to react to
acute stressors without increasing inflammation. Increased inflammation correlates with the
etiology of many pathologic conditions including, but not limited to, mood disorders, further
enforcing the delicate relationship between the brain and gut.
In an attempt to prove the correlation of gut microbiome composition and depression in
humans, Naseribafrouei et al. (2014) performed a partially double-blind study. They had
assessed the research regarding animal models and wanted to pinpoint specificities in the human
model. In order to prove this, they recruited 37 patients from a mental clinic with depression
ranging from mild to severe, and 18 control patients with no diagnosable depression. The control
group was recruited based on similar age and gender distribution.
Fecal samples were collected from all participants and were analyzed using DNA
extraction and sequencing, which has been previously validated during irritable bowel syndrome
(IBS) research. The results showed that there were no significant differences in bacteria species
richness or diversity between the depressed and control group. However, there was a significant
correlation of underrepresentation of Bacteridetes phylum (p<0.05). This is consistent with
previous studies that associate low Bacteroidetes with obesity and low-grade inflammation.
Overgrowth of Alistipes (p<0.007) and Oscillibacter (p<0.03) were both associated with the
depression group. Of note, Oscillibacter has valceric acid as its main metabolite. Valceric acid
will bind to gamma-Aminobutyric acid-a (GABAa) receptors because it is structurally similar to
GABA. While the role of valceric acid in the gut is unclear, its overgrowth can be associated
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with decreased GABA binding and therefore, correlates with the pathophysiology of depression.
The weakness of this study is a small sample size, but is beneficial to this study because it shows
specific bacteria associated with the development of mood disorders.
A study by Zheng et al. (2016) evaluated the gut microbiome of patients with MDD by
analyzing alterations in gut bacteria and hippocampal metabolism. Like similar studies
performed by this group, fecal transplants from patients with MDD were transplanted into mice
and multiple tests assessing anxiety and depressive-like behaviors were evaluated. This study
evaluated 58 MDD patients and 63 healthy controls. In order to further establish a causative role,
this study attempts to dive farther and specifically identify bacterial families and metabolic
pathways within the hippocampus that are affected. Fecal transplants were randomly chosen
from those with MDD and healthy patients to colonize the mice. They were kept in separate
environments to prevent cross-contamination. Behavioral tests were performed at one and two
weeks. After the second week, the mice were killed, and fecal samples immediately collected.
It was well documented in this study and their previous cohort study that fecal transplants
from patients with depression induce depressive-like behaviors in mice. This is exhibited in
decreased performance in the center motion distance on OFT and increased immobility (p<0.05).
Further examination through DNA extraction of gut microbiome in patients with MDD showed
an overrepresentation of 29 bacterial families. Of special interest were three species that were
implicated as playing a more integral role in depressive symptoms; phylum Firmicutes,
Bacteriodetes, and Actinobacteria. In addition, the hippocampi of all mice within the study were
compared and found to have profound differences in metabolic pathways involving
carbohydrates and amino acids. Other anatomical areas of the brain were not addressed in this
study. This does provide some limitation to this study because depression and anxiety are known
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to affect multiple regions within the brain. An additional limitation to this study was that it
identified gut bacteria alterations in MDD, however, other neuropsychiatric disorders were not
evaluated.
Gut microbiome transplants as therapy
Now that the relationship between the gut and brain has been established, treatment
involving alterations of the gut microbiome can be further researched. Multiple methods have
been studied regarding how to replace pathologic bacteria, but in the interest of this study, direct
replacements of microbiome are being evaluated.
Akkasheh et al. (2016) performed this eight-week, randomized, double-blind, placebocontrolled trial to evaluate the effects of probiotics on depressive symptoms in patients with
MDD as defined by the Beck Depression Inventory (BDI). Forty patients were included and
randomly assigned to intervention and placebo groups. The intervention group included a once
daily, probiotic supplementation of Lactobacillis casei and Bifidobacterium bifidum. Dietary and
activity logs were collected from the enrolled members and showed no significant difference.
The patients were also instructed not to change their daily habits or dietary intake during the
trial.
In addition to evaluating the BDI at the end of the studies, other secondary markers such
lipid concentrations, fasting blood glucose (FBG), C-reactive protein (CRP), total antioxidant
capacity (TAC), and glutathione (GSH) were monitored to evaluate insulin metabolism and
oxidative stress. Five patients left the study, leaving a total of 35 patients that participated in the
study. A 90% compliance rate was achieved in the daily administration of probiotic or placebo
capsules.
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The eight-week reevaluation of the BDI scores showed that the participants receiving the
probiotic capsules had significantly lower scores (p<0.001) when compared to the placebo group.
Also, they were found to have statistically significant lower insulin levels (p<0.03) and hs-CRP
(p<0.03) and statistically higher levels of GSH (p<0.02). There was no statistical significance in
levels of lipid profiles, FPG, or TAC. Limitations of the study were short duration and small
sample size. Also, since multiple probiotic strains were administered simultaneously, it is unclear
which strain caused the observed effect.
Bambling, Edwards, Hall, and Vietta (2017) performed a small, single group,
intervention-only study, which included 16 qualifying participants with depression that was
resistant to selective serotonin reuptake inhibitors (SSRIs). This study was a follow-up to a
previous study that showed promising results, but only had four participants. The goal of the
study was to assess the role that probiotics play in reducing symptoms of depression in
combination with standing treatments. This was done by evaluating participants using BDI,
Outcome Questionnaire 45 (OQ45) and Quality of Life (QoL). Participants were treated with
their current medication regimen along with adding daily dosing of probiotics. The study
intervention included twice daily dosing of probiotic capsules with Lactobacillus acidophilus,
Bifidobacterium bifidum, Streptococcus thermophiles and magnesium orotate.
Sixteen participants completed the study with good adherence to the intervention. At the
eight-week mark, there was statistically significant lower BDI scores (p = 0.005) and OQ45 (p =
0.001). There were borderline statistically significant changes in QoL scores (p = 0.052).
Limitations of this study are small sample size, however; this study serves as a pilot study and
did indicate a need for a larger study. It does correlate with the previous research that has shown
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improved depression scores with the administration of magnesium orotate. It also must be noted
that the lack of a control group does weaken the study, but shows the need for further research.
Within the central nervous system (CNS), gamma-Aminobutyric acid (GABA) receptors
play a significant role in neuronal function and health. Alterations in GABA receptors are
believed to play a vital role in the development of mood disorders, such as depression and
anxiety. A study by Bravo et al. (2011) observed that treatment with Lactobacillus rhamnosus
(JB-1) modulates the expression of multiple GABA receptors within the CNS. Additionally,
they observed that administration of JB-1 reduces corticosterone level associated with a stress
response. When monitoring behaviors, mice fed with JB-1 showed more antidepressant
behaviors and less activities associated with anxiety. This implies the HPA axis and bidirectional
relationship between the gut and brain.
This study establishes a pathological gut-brain connection in patients with mood
disorders and is essential to establishing possible treatment through gut modulation. The data
suggests that by treating patients with nonpathogenic bacteria, we can target and alter the
receptors within the CNS that are causative of neurobehavioral disease. Specifically, the GABA
receptors which are currently the target of pharmacological interventions. The weakness of this
study is that it does not show specific protein changes but only shows changes on a mRNA level
which leaves to question the complex intracellular cascades that may also be affected.
The following meta-analysis is important because it analyzes multiple studies. Thus,
researchers were able to minimize some degree of error that individual studies may possess. In
order to be included in this analysis, Huang, Wang, and Hu (2016) only included studies that
were randomized-control trials, used probiotics as an intervention, used similar scales for
evaluating depression symptoms, scales reported were mean standard deviations, and included a
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control group. They evaluated the potential use of probiotics to improve depression scores in five
studies, which looked at 183 cases and 182 control subjects.
While most of the individual studies did not show significant results, information from all
five studies combined showed a significant reduction in depression scores in patients aged 60
and younger with probiotic supplementation, MD = -.30 (95% CI: -0.51- -0.09), p = 0.005. They
included patients with existing depression and no diagnosed depression. By looking at both
healthy and affected patients, it suggests that there is a possible role for probiotics in not only the
treatment, but also the prevention of depression.
Rao et al. (2009) performed a study that looked at treating Chronic Fatigue Syndrome
(CFS) with Lactobacillus casei. This study is somewhat different than this paper’s theme of
treating depression and anxiety, however, it is beneficial research because anxiety is the most
reported symptom in patients with CFS. This randomized, double-blind, placebo-controlled pilot
study looked at 39 participants with CFS who were randomly placed in placebo groups or treated
with 24 billion colony forming units of L. casei probiotic. They were evaluated using BDI prior
to and after the intervention.
In order to be included in the study, participants ranging 18-65 were screened from a pool
of patient with CFS. Screened individuals that met criteria for a psychiatric disorder other than
anxiety, depression, or were medically unstable were excluded. Of the 39 remaining participants,
groups were randomized. Stool samples were collected prior to the initiation and analyzed for
microbiome composition. After the eight-week trial, stool samples were again analyzed.
Lactobacillus measurements in the placebo group participants showed a 43.8% increase and
73.7% increase in the treatment group. The increase with direct treatment would be expected,
however, when the fecal total of Bifidobacteria was measured, it showed a 37.5% increase versus
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a 73.7% increase in the treatment group. This is relevant because this strain of probiotic was not
directly treated and showed increased growth of “healthy” bacteria through supplementation with
Lactobacillus. Of additional significance, patients with CFS typically have lower levels of
Bifidobacteria reported.
Participants receiving the intervention had significantly lower BDI scores at the end of
the eight-week trial (p<0.011). While this study certainly has limitations with sample size, it is
one of the only studies to look at an individual probiotic strain to treat symptoms of anxiety. It is
also beneficial because of its data showing that Lactobacillus supplementation can completely
displace pathogenic gut bacteria by the changes in gut microbiome constitution. This correlates
with current research regarding treatment of Clostridium difficile (C. dif). Bowel function was
not assessed in this study, although poor bowel function can often be a significant symptom in
patients with CFS. While this study is encouraging, it should be motivation for additional, larger
studies to be performed.
Kazemi, Noorbala, Azam, Eskandari and Djafarian (2019) performed a larger study
involving 81 participants that assessed the effect of probiotics and prebiotic supplementation on
BDI scores. While probiotics work by directly instilling bacteria within the gut, treatment with
probiotics are aimed at fertilizing favorable bacteria and therefore, stimulating growth. This
eight-week study was conducted as a double-blind, placebo-controlled, randomized trial and
initially involved 110 patients with diagnosed depression. Eighty-one subjects finished the study
and the results supported the role that probiotics play in improving symptoms of depression.
Participants were randomly assigned to receive probiotics, prebiotics, or placebo for eight
weeks. The probiotics given were Lactobacillus helveticus and Bifidobacterium longus, which
has been previously studied in smaller studies as having anti-inflammatory properties. BDI
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scores were significantly lower in patients treated with the probiotic versus the placebo or
prebiotic (p = 0.042). In addition to BDI scores, kynurenine/tryptophan ratios were measured and
found to be significantly lower in patients treated with probiotics versus the placebo group after
adjustments for serum isoleucine (p = 0.048). There was no significance in the prebiotic group.
This is of special interest because the kynurenine tryptophan pathway has been previously
implicated in the pathophysiology of depression. It is believed that the metabolites of the
kynurenine tryptophan pathway cause a deficiency in serotonin, a well-known target in
depression medications. This study is beneficial because it evaluates symptoms and etiology of
the disease. While the study contains strong data to support the use of probiotics, an important
limiting factor is that patients were not treated with the same antidepressant regimens.
The following study by Xu et al. (2018) evaluates the relationship between addiction
disorders and the development of a coexisting mood disorder. While the etiology of alcohol
addiction is not completely understood, it is one of the most prevalent neuropsychiatric diseases
with over 3 million deaths annually. One of the key components of chronic alcoholism is the
development of depression and anxiety. This is believed to be caused by the alterations in gut
microbiome caused by chronic alcohol intake. Xu et al. attempted to not only prove the gut
microbiome alterations caused by chronic alcohol intake, but also to treat the randomized
participants with FMT from healthy donors to show the protective effect of a healthy gut against
the development of mood disorders.
In order to first establish chronic alcohol usage effect on behavior, they recorded the
activity of 110 mice that were in the control group or treated with increased levels of alcohol
ranging from two to eight percent over a three-week period. Results of the study showed that the
alcohol mice traveled less distance in the inner zone (P = 0.0009), spent less time in the inner
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zone (P = 0.0078), had decreased mobility in the tail suspension test (TST) (P= 0.0220), and had
less mobility time in the swim test (P = 0.0360). All are indicative of increased anxiety and
depression-like behaviors.
After the depression and anxiety behaviors had been established, mice were randomly
divided and treated with FMT from three healthy males with no history of depression. Groups
were initially treated for two, which showed decreased immobility during the TST (P = 0.0026).
Otherwise, no difference was observed in the other four behavioral tests. Since the results did
not correlate with the expected results, the second phase of the test was repeated with mice
receiving FMT for a total of five weeks. The results of this test revealed improved anxiety-like
behaviors in the open field test total distance (P < 0.0001) and inner distance (P = 0.0003).
Additionally, an increased TST (P < 0.001) correlated with improved depression behaviors. The
results of this study showed that an increased length of FMT treatment improved symptoms in
alcohol induced anxiety and depression. Interestingly, this study did not find any statistical
reduction in alcohol preference. This means that while FMT may be a potential target for
treatment of depression and anxiety, it did not affect the underlying cause, alcoholism.

Discussion
In patients with depression or anxiety, do gut microbiota transplants improve symptoms of
depression?
Research by Bambling et al. (2017), found that twice daily dosing of probiotic capsules
with Lactobacillus acidophilus, Bifidobacterium bifidum, Streptococcus thermophiles, and
magnesium orotate improved depression scores in participants with SSRI resistant depression. A
larger study by Kazemi et al. (2019), found an improvement in BDI depression scores after
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treatment with a probiotic. The study also found that pre-treatment with a probiotic did not affect
the BDI scores, which may be attributed to the replacement of pathologic bacteria in
symptomatic patients in contrast to participants not exhibiting signs of depression. Of particular
interest, because of large sample size, the meta-analysis performed by Huang et al. (2016),
showed decreased depression scores in participants under 60 with probiotic supplementation.
While the studies are certainly limited by sample size, there is significant data to suggest the
need for further research into microbiome alterations as treatment for mood disorders.
In patients with depression or anxiety, is there an alteration in gut microbiota associated
with the development of moods disorders?
According to the researched performed by Jianguo et al. (2019), the study analyzed gut
microbiome and quantified neurotransmitters in participants with anxiety and depression. Their
research found a reduction in all 12 neurotransmitters that were evaluated. Specifically,
neurotransmitters that are the target of medication therapy in the current treatment of anxiety and
depression. Additionally, Naseribafrouei et al. (2012), found an overrepresentation of Alistipes
and Oscillibacter bacteria in participants with diagnosed depression. In order to further connect
bacterial overgrowth and decreased neurotransmitters, Lou et al. (2012), found that the
overgrowth of pathologic bacteria increased inflammatory markers within the brain, which in
turn caused decreased neurotransmitters. The information within these studies show more than a
correlation between gut bacteria and neurologic health. They also show a pathophysiologic cause
between the gut and mood disorders by quantifying neurotransmitters that are the current target
of treatment.
Applicability to Clinical Practice
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Mood disorders, such as anxiety and depression, will be seen very frequently in all facets
of health care, because it affects more than 8% of the population, often simultaneously. It is
important to have a good understanding of etiology and the most up-to-date treatments. Current
treatment regimens are not well targeted and are currently aimed at treating the deficiency in
neurotransmitters and not treating the underlying problem. Patients will often have to experiment
with multiple medications to find a regimen that is effective for them and these can become
ineffective for many people over time.
My research found an underlying cause of mood disorders that links the gut microbiome,
which creates another target of treatment. Increased growth of pathologic bacteria, inflammatory
markers, and decreased neurotransmitters are all seen in individuals affected with mood
disorders. Transplantation of their gut microbiome reproduces their symptoms in previously
healthy people. My research also found lower depression scores when pathologic bacterium were
replaced through transplantation with probiotics. This research is not only a compelling cause for
further research into direct replacements, but also shows that probiotic supplementation may be
beneficial with the current level of research.
In the future, patients may be able to have their gut microbiome analyzed and have a
targeted treatment specifically designed for them. Additionally, information from these studies
may be correlated with current treatment to provide patients with resistant mood disorders better
treatment regimens.
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